News about "Merck"

Merck Signs Exclusive Global License Deal with Hansoh Pharma for Oral GLP-1 Receptor Agonist

Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535.

Merck | 19/12/2024 | By Aishwarya |  174

Merck Signs MoU with Siemens to Accelerate Digital Transformation Technology

The MoU makes Siemens a preferred global supplier and strategic partner for Smartfacturing technologies, paving the way for transformative projects across Merck's three business sectors.

Merck | 18/09/2024 | By Aishwarya |  190

Merck to Acquire CN201 from Curon Biopharmaceutical

CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for treating patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively.

Merck | 14/08/2024 | By Aishwarya |  102

Merck Acquires Mirus Bio to Advance Viral Vector Bioprocessing

Merck has completed the acquisition of Mirus Bio for approximately USD 600 million (around EUR 550 million), following regulatory clearances and the fulfillment of other customary closing conditions.

Merck | 03/08/2024 | By Aishwarya |  192

Merck Signs MoU with Gene Therapy Research Institution

Merck has signed a non-binding Memorandum of Understanding (MoU) with Gene Therapy Research Institution Co., Ltd. (GTRI), a Japanese clinical-stage biotech start-up specializing in gene therapy using adeno-associated virus (AAV) vectors.

Merck | 25/07/2024 | By Aishwarya |  191

Merck Begins Commercial Production of GMP-Compliant Manufacturing Line for CCM in China

Merck has started the commercial production of its first GMP (Good Manufacturing Practices) compliant manufacturing line for cell culture media (CCM) in China.

Merck | 16/07/2024 | By Aishwarya |  130

Merck Announces Update on Xevinapant Program in Locally Advanced Head and Neck Cancer

Merck has discontinued the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

Merck | 27/06/2024 | By Aishwarya |  130

Merck Signs MoU with KAIST to Boost Scientific Research

Merck has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST).

Merck | 31/05/2024 | By Aishwarya

Merck Announces Acquisition of EyeBio

Merck has signed a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.

Merck | 30/05/2024 | By Aishwarya |  164

Merck Signs Definitive Deal to Acquire Mirus Bio for USD 600 Million

Merck has signed a definitive agreement to acquire Mirus Bio for USD 600 million.

Merck | 27/05/2024 | By Aishwarya |  148